logo
logo
INSM stock ticker logo

Insmed Incorporated

NASDAQ•INSM
CEO: Mr. William H. Lewis J.D., M.B.A.
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2000-06-01
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Contact Information
700 US Highway 202/206, Bridgewater, NJ, 08807, United States
908-977-9900
www.insmed.com
Market Cap
$31.01B
P/E (TTM)
-24.1
466.5
Dividend Yield
--
52W High
$212.75
52W Low
$60.40
52W Range
55%
Rank71Top 99.6%
1.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$263.84M+0.00%
4-Quarter Trend

EPS

-$1.54+0.00%
4-Quarter Trend

FCF

-$294.19M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Product Revenues Surge Total product revenues reached $606.4M in 2025, up 66.7% from $363.7M in 2024, driven by new product sales.
BRINSUPRI US Commercial Sales US commercial sales of BRINSUPRI generated $172.7M following its FDA approval in August 2025, marking a major launch.
ARIKAYCE International Growth ARIKAYCE international sales grew 40.9% to $153.5M in 2025, demonstrating successful expansion outside the US market.
Cash and Securities Position Cash and marketable securities totaled $1.43B ($510.4M cash) as of December 31, 2025, supporting near-term operations.

Risk Factors

Net Loss Widened Significantly Net loss widened to $(1,276.8M) in 2025; company has history of operating losses since 2010, requiring future capital.
Full ARIKAYCE Approval Contingent Full ARIKAYCE approval depends on successful ENCORE trial data expected by April 2026; failure risks material adverse effect.
Operating Expenses Increased Sharply R&D expenses rose 28.9% to $771.1M; SG&A expenses increased 52.1% to $701.2M in 2025 due to headcount and commercial readiness.
IP Protection and Litigation Risk Success highly dependent on protecting proprietary technology; litigation risk remains high globally, potentially diminishing asset value.

Outlook

ARIKAYCE Label Expansion Plan Plan to submit sNDA for ARIKAYCE label expansion in H2 2026 if ENCORE trial data confirm clinical benefit.
BRINSUPRI International Decisions Anticipate regulatory decisions for BRINSUPRI in UK and Japan during 2026; evaluating US policy impact on future launches.
Advance Pipeline Programs Initiate Phase 3 TPIP study for PAH in H1 2026 and advance INS1148 into Phase 2 development programs.
Capital Deployment Strategy Control spending, prudently deploying capital to support best return-generating opportunities while managing substantial debt obligations.

Peer Comparison

Revenue (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
HUM stock ticker logoHUM
$129.66B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%

Gross Margin (Latest Quarter)

ONC stock ticker logoONC
90.5%
+3.1pp
INSM stock ticker logoINSM
82.5%
-18.6pp
HLN stock ticker logoHLN
65.0%
+0.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TAK$57.53B80.81.6%31.5%
CAH$51.07B30.7-58.9%15.5%
HLN$45.30B22.29.4%26.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
41.7%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026
|
EPS:-$0.99
|
Revenue:$300.92M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data